Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease

被引：5

作者：

Papamichael, Konstantinos ^{[1
,7
]}

Vande Casteele, Niels ^{[2
]}

Abraham, Bincy P. ^{[3
]}

Ritter, Timothy ^{[4
]}

Jain, Anjali ^{[5
]}

Cheifetz, Adam S. ^{[6
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Ctr Inflammatory Bowel Dis, Boston, MA USA

[2] Univ Calif San Diego, Dept Med, La Jolla, CA USA

[3] Houston Methodist Hosp, Dept Med, Houston, TX USA

[4] GI Alliance Res, Southlake, TX USA

[5] Prometheus Labs, San Diego, CA USA

[6] Beth Israel Deaconess Med Ctr, Ctr Inflammatory Bowel Dis, Boston, MA USA

[7] Beth Israel Deaconess Med Ctr, Ctr Inflammatory Bowel Dis, 330 Brookline Ave, Boston, MA 02215 USA

来源：

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2023年 / 21卷 / 11期

关键词：

FAILURE;

D O I：

10.1016/j.cgh.2022.10.037

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：2978 / +

页数：5

共 50 条

[31] Differential Serum-intestinal Dynamics of Infliximab and Adalimumab in Inflammatory Bowel Disease Patients
Bar-Yoseph, Haggai
Blatt, Alexandra
Gerassy, Shiran
Pressman, Sigal
Mousa, Amjad
Sabo, Edmond
Waterman, Matti
Ungar, Bella
Ben-Horin, Shomron
Chowers, Yehuda
JOURNAL OF CROHNS & COLITIS, 2022, 16 (06): : 884 - 892
[32] False Positive Infliximab Levels Detected in Patients Treated with Adalimumab for Inflammatory Bowel Disease
Abraham, Bincy
Chiorean, Michael
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S627 - S627
[33] Determinants of Immunogenicity in Children With Inflammatory Bowel Disease Receiving Infliximab
Hofmekler, Tatyana
Bertha, Madeline
McCracken, Courtney
McKinnon, Elizabeth
Kugathasan, Subra
Sauer, Cary
GASTROENTEROLOGY, 2014, 146 (05) : S374 - S374
[34] Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab
Loveikyte, Roberta
Bourgonje, Arno R.
van der Reijden, Johannes J.
Bulthuis, Marian L. C.
Hawinkels, Lukas J. A. C.
Visschedijk, Marijn C.
Festen, Eleonora A. M.
van Dullemen, Hendrik M.
Weersma, Rinse K.
van Goor, Harry
van der Meulen-de Jong, Andrea E.
Dijkstra, Gerard
INFLAMMATORY BOWEL DISEASES, 2023, 29 (08) : 1272 - 1284
[35] The effect of induction therapy with infliximab or vedolizumab on hepcidin and iron status in patients with Inflammatory Bowel Disease
Loveikyte, R.
Bourgonje, A. R.
van der Reijden, J. J.
Bulthuis, M. L. C.
Hawinkels, L. J. A. C.
van Goor, H.
van der Meulen-de Jong, A. E.
Dijkstra, G.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I244 - I245
[36] Response and Healthcare Resource Utilization in Inflammatory Bowel Disease Patients Treated With Either Infliximab or Vedolizumab
Sarles, Harry E., Jr.
Hardin, Thomas C.
Kuten, Samantha A.
Van Anglen, Lucinda J.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S485 - S485
[37] The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab
Harrington, Jill E.
Hamilton, Rachel E.
Ganley-Leal, Lisa
Farraye, Francis A.
Wasan, Sharmeel K.
CROHNS & COLITIS 360, 2020, 2 (04) : 1 - 10
[38] Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease
Merras-Salmio, Laura
Kolho, Kaija-Leena
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2017, 64 (02): : 272 - 278
[39] Predictors of Immunogenicity to Infliximab among Patients with Inflammatory Bowel Disease: Does Ethnicity Matter?
Veisman, Ido
Yablecovitch, Doron
Kopylov, Uri
Eliakim, Rami
Ben-Horin, Shomron
Ungar, Bella
ISRAEL MEDICAL ASSOCIATION JOURNAL, 2021, 23 (12): : 788 - 793
[40] ANTI-DRUG ANTIBODIES (ADA): ASSAY PERFORMANCE IN PATIENTS TREATED FOR INFLAMMATORY BOWEL AND RHEUMATIC DISEASE WITH BIODRUGS, ADALIMUMAB AND INFLIXIMAB
O'Donnell, J.
Liu, J.
Keating, P.
Hock, B.
Spellerberg, M.
Barclay, M.
Stamp, L.
INTERNAL MEDICINE JOURNAL, 2017, 47 : 15 - 15

← 1 2 3 4 5 →